Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.43 |
| ▸ | JAK1 | P23458 | 8/20 | 0.43 |
| ▸ | JAK3 | P52333 | 4/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.43 |
| ▸ | PAK4 | O96013 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | LTK | P29376 | 2/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.43 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.43 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20567894 | 1.00 | JAK2 (0.43) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL20567774 | 0.93 | JAK2 (0.42) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL20567771 | 0.93 | JAK2 (0.42) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL20567741 | 0.92 | JAK2 (0.42) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL20567739 | 0.92 | JAK2 (0.42) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL22349007 | 0.92 | JAK2 (0.43) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL20567872 | 0.91 | JAK2 (0.43) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL20567869 | 0.91 | JAK2 (0.43) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL20567752 | 0.91 | JAK1 (0.41) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL20567751 | 0.91 | JAK1 (0.41) | JAK2JAK1JAK3TYK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032250-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-02-04 | — | — | US | disclosed |
| US-20210032250-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-02-04 | — | — | US | disclosed |
| US-10745405-B2 | Glucuronide prodrugs of Janus kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745405-B2 | Glucuronide prodrugs of Janus kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3609899-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2020-02-19 | — | — | EP | disclosed |
| CN-110662747-A | Glucuronide prodrugs of Janus kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2020-01-07 | — | — | CN | disclosed |
| WO-2018217700-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180339990-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032250-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | JAK1, UGT1A1, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 5/4885 |
| US-10745405-B2 | Glucuronide prodrugs of Janus kinase inhibitors | JAK1, UGT1A1, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 5/4885 |
| US-20180339990-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | JAK1, UGT1A1, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.